000 | 01434 a2200445 4500 | ||
---|---|---|---|
005 | 20250513204938.0 | ||
264 | 0 | _c20000407 | |
008 | 200004s 0 0 eng d | ||
022 | _a0160-6689 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aJeste, D V | |
245 | 0 | 0 |
_aTardive dyskinesia in older patients. _h[electronic resource] |
260 |
_bThe Journal of clinical psychiatry _c2000 |
||
300 |
_a27-32 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
650 | 0 | 4 | _aBenzodiazepines |
650 | 0 | 4 | _aClinical Trials as Topic |
650 | 0 | 4 |
_aClozapine _xadverse effects |
650 | 0 | 4 |
_aDibenzothiazepines _xadverse effects |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xepidemiology |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIncidence |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aOlanzapine |
650 | 0 | 4 |
_aPirenzepine _xadverse effects |
650 | 0 | 4 |
_aPsychotic Disorders _xdrug therapy |
650 | 0 | 4 | _aQuetiapine Fumarate |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 |
_aRisperidone _xadverse effects |
773 | 0 |
_tThe Journal of clinical psychiatry _gvol. 61 Suppl 4 _gp. 27-32 |
|
999 |
_c10692810 _d10692810 |